Litigation Details for WILSON v. FOAMIX PHARMACEUTICALS LTD. (D.N.J. 2019)

WILSON v. FOAMIX PHARMACEUTICALS LTD. (D.N.J. 2019)

Docket	3:19-cv-21563	Date Filed	2019-12-18
Court	District Court, D. New Jersey	Date Terminated	2020-03-25
Cause	28:1331 Fed. Question: Securities Violation	Assigned To	Michael Andre Shipp
Jury Demand	Plaintiff	Referred To	Tonianne J. Bongiovanni
Parties	TONY BRUNO
Patents	10,398,641
Attorneys	EVAN JASON SMITH
Firms	Brodsky & Smith, LLC
Link to Docket	External link to docket

Details for WILSON v. FOAMIX PHARMACEUTICALS LTD. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-12-18				External link to document
2019-12-17	1	Complaint	announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,398,641, covering a method …This newly issued patent, which expires in September 2037, is the latest U.S. patent to be issued to the	External link to document

WILSON v. Foamix Pharmaceuticals Ltd. | 3:19-cv-21563 Litigation Analysis

Last updated: February 19, 2026

This report summarizes the litigation history and key developments in the patent infringement case WILSON v. FOAMIX PHARMACEUTICALS LTD. (3:19-cv-21563). The case involves allegations of infringement of U.S. Patent No. 9,089,588, directed to formulations for treating dermatological conditions.

What are the Core Allegations in the Lawsuit?

Plaintiff Michael Wilson alleges that Foamix Pharmaceuticals Ltd. and Foamix Ltd. (collectively, Foamix) infringed U.S. Patent No. 9,089,588 by making, using, selling, offering for sale, and importing products that embody the patented invention. The patent describes pharmaceutical foam compositions comprising a propellant, an emulsifier, and an active pharmaceutical ingredient (API). Wilson asserts that Foamix's commercial products, including Aer DiCaprio, Aer Solese, and Aer Cleanser, infringe at least one claim of the '588 patent.

What is the Asserted Patent and Its Key Claims?

U.S. Patent No. 9,089,588 was filed on June 20, 2013, and issued on July 28, 2015. The patent is titled "Pharmaceutical foam compositions and methods of preparation and use."

Key features of the '588 patent include:

• Formulation Type: Pharmaceutical foam compositions.
• Components: Typically comprises a propellant, an emulsifier, and an active pharmaceutical ingredient (API).
• Method of Use: For treating dermatological conditions.
• Claim 1 (representative of core claims): Claims a pharmaceutical foam composition comprising:
  • A propellant in an amount of from about 1% to about 20% by weight of the composition.
  • An emulsifier in an amount of from about 0.1% to about 10% by weight of the composition.
  • An active pharmaceutical ingredient (API) in an amount of from about 0.1% to about 20% by weight of the composition.
  • The composition is free of volatile organic compounds (VOCs).

The patent describes advantages such as improved delivery of the API, enhanced patient compliance due to cosmetic elegance, and suitability for sensitive skin.

What are Foamix's Primary Defenses?

Foamix has raised several defenses to the infringement allegations, including:

• Non-Infringement: Foamix asserts that its accused products do not fall within the scope of the asserted claims of the '588 patent. This defense often hinges on detailed analysis of the composition of their products compared to the precise language of the patent claims.
• Invalidity: Foamix has challenged the validity of the '588 patent, arguing that it is invalid due to anticipation or obviousness over prior art. Prior art can include existing patents, publications, and public uses that predate the filing of the patent.

What is the Procedural History of the Case?

The litigation commenced on December 6, 2019, with Wilson filing a complaint in the U.S. District Court for the District of New Jersey. Foamix filed its answer and counterclaim for a declaratory judgment of non-infringement and invalidity on January 27, 2020.

Key procedural milestones include:

• December 6, 2019: Complaint filed.
• January 27, 2020: Foamix files Answer and Counterclaims.
• Ongoing: Discovery, including document production, interrogatories, and depositions.
• July 24, 2020: Foamix files a Motion to Dismiss Counterclaims, which was subsequently denied.
• October 27, 2020: Parties stipulate to stay discovery pending the outcome of potential Inter Partes Review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO).
• November 23, 2020: Foamix files a Petition for Inter Partes Review (IPR) of the '588 patent with the Patent Trial and Appeal Board (PTAB).
• April 15, 2021: PTAB institutes the IPR.
• September 17, 2021: The District Court lifts the stay on discovery.
• June 29, 2022: PTAB issues a final written decision in the IPR, finding claims 1, 3-7, 9-10, 12-13, 15-17, and 19-20 of the '588 patent unpatentable. Claims 2, 8, 11, 14, 18, and 21 were found not unpatentable.
• August 29, 2022: Foamix files a motion for summary judgment of non-infringement and invalidity in light of the PTAB's IPR decision.
• February 2, 2023: The District Court grants Foamix's motion for summary judgment, dismissing Wilson's infringement claims. The court found that the claims deemed unpatentable by the PTAB were indeed invalid, and the remaining claims were not infringed by Foamix's products.
• March 2, 2023: Wilson files a Notice of Appeal to the United States Court of Appeals for the Federal Circuit.

What Was the Outcome of the Inter Partes Review (IPR)?

The IPR proceedings before the PTAB were a significant factor in the litigation's trajectory. Foamix petitioned for a review of the patentability of claims 1-21 of the '588 patent.

Key findings of the PTAB's final written decision (June 29, 2022):

• Claims Found Unpatentable: Claims 1, 3-7, 9-10, 12-13, 15-17, and 19-20 were found unpatentable based on anticipation and/or obviousness over prior art, including U.S. Patent Application Publication No. 2013/0028788 and U.S. Patent No. 7,553,814.
• Claims Found Not Unpatentable: Claims 2, 8, 11, 14, 18, and 21 were found not unpatentable.

This outcome bifurcated the patent, with a substantial portion of the claims being invalidated.

How Did the District Court Rule on Summary Judgment?

Following the PTAB's IPR decision, Foamix moved for summary judgment. The District Court granted this motion, effectively ending the litigation at the district court level.

Basis for the District Court's ruling (February 2, 2023):

• Invalidity of Key Claims: The court relied on the PTAB's finding that claims 1, 3-7, 9-10, 12-13, 15-17, and 19-20 were unpatentable. As claim 1 is representative of the scope of these invalidated claims, and other claims were found infringed in the complaint, their invalidity precluded infringement.
• Non-Infringement of Remaining Claims: The court also found that Foamix's accused products did not infringe the claims that the PTAB had found not unpatentable (claims 2, 8, 11, 14, 18, and 21). This analysis likely involved a claim construction process where the court determined the meaning of specific terms in the remaining claims, and then compared those constructions to the composition of Foamix's products. For example, the court might have concluded that the accused products did not meet a specific limitation of these remaining claims, such as a particular concentration range or the absence of a specific element.

The court concluded that no genuine dispute of material fact existed and that Foamix was entitled to judgment as a matter of law.

What is the Current Status of the Case?

The case is currently on appeal. Michael Wilson appealed the District Court's grant of summary judgment to the U.S. Court of Appeals for the Federal Circuit on March 2, 2023. The appeal will review the District Court's claim construction, its application of the PTAB's IPR decision, and its findings regarding non-infringement of the remaining claims.

What are the Implications for Pharmaceutical Patent Litigation?

This case illustrates several critical aspects of pharmaceutical patent litigation:

• Impact of IPR Proceedings: IPRs continue to be a powerful tool for defendants in patent litigation, offering a potentially faster and less expensive route to challenging patent validity than district court invalidity defenses. The PTAB's findings can significantly influence or decide the outcome of district court cases.
• Claim Construction is Paramount: The interpretation of patent claims (claim construction) is central to both infringement and validity analyses. Disagreements over claim scope can lead to vastly different legal outcomes.
• Interplay Between PTAB and District Court: While PTAB decisions carry significant weight, district courts still conduct their own independent analyses of claim construction and infringement, especially for claims not invalidated by the PTAB.
• Strategic Importance of Prior Art: Thorough prior art searches and analysis are essential for both patent prosecution and invalidity challenges. The '588 patent was found wanting in this regard.
• Compositional Differences Matter: For drug products, precise compositional differences are crucial. Even minor deviations can avoid literal infringement, though the doctrine of equivalents may still apply in some circumstances.

Key Takeaways

• WILSON v. FOAMIX PHARMACEUTICALS LTD. (3:19-cv-21563) involved allegations of infringement of U.S. Patent No. 9,089,588.
• Foamix successfully challenged the patent's validity through an Inter Partes Review (IPR) at the USPTO, leading to the invalidation of key claims.
• The District Court granted summary judgment in favor of Foamix, finding that the invalidated claims could not be infringed and that Foamix did not infringe the remaining valid claims.
• The case is currently on appeal to the U.S. Court of Appeals for the Federal Circuit, with the outcome of the appeal being determinative for the future of the litigation.
• The litigation highlights the strategic importance and effectiveness of IPR proceedings in patent defense and the critical role of claim construction in infringement analysis.

Frequently Asked Questions

What specific products of Foamix were accused of infringing the '588 patent?

The accused products included Aer DiCaprio, Aer Solese, and Aer Cleanser.

What was the main reason for the PTAB's decision to invalidate claims of the '588 patent?

The PTAB found the claims unpatentable based on anticipation and/or obviousness over identified prior art references, meaning the claimed invention was not new or was an obvious variation of existing technology.

Did the District Court completely dismiss all claims against Foamix, or are some still pending?

The District Court granted summary judgment in favor of Foamix, dismissing Wilson's infringement claims. The case's continuation now rests on the outcome of the appeal.

What does "anticipation" mean in the context of patent invalidity?

Anticipation means that a claimed invention was already described in the prior art in such a way that it would have been obvious to a person of ordinary skill in the art at the time of the invention.

If the Federal Circuit overturns the District Court's decision, what happens next?

If the Federal Circuit overturns the District Court's grant of summary judgment, the case would likely be remanded back to the District Court for further proceedings, potentially including a trial on the merits of the non-infringement and validity defenses for the remaining claims.

---

Citations

[1] Complaint for Patent Infringement, Wilson v. Foamix Pharmaceuticals Ltd., No. 3:19-cv-21563 (D.N.J. Dec. 6, 2019). [2] Answer and Counterclaims of Defendants Foamix Pharmaceuticals Ltd. and Foamix Ltd., Wilson v. Foamix Pharmaceuticals Ltd., No. 3:19-cv-21563 (D.N.J. Jan. 27, 2020). [3] Order, Wilson v. Foamix Pharmaceuticals Ltd., No. 3:19-cv-21563 (D.N.J. July 24, 2020). [4] Order, Wilson v. Foamix Pharmaceuticals Ltd., No. 3:19-cv-21563 (D.N.J. Oct. 27, 2020). [5] U.S. Patent No. 9,089,588. [6] Petition for Inter Partes Review, Foamix Pharmaceuticals Ltd. v. Michael Wilson, IPR2021-00148 (P.T.A.B. Nov. 23, 2020). [7] Institution Order, Foamix Pharmaceuticals Ltd. v. Michael Wilson, IPR2021-00148 (P.T.A.B. Apr. 15, 2021). [8] Order, Wilson v. Foamix Pharmaceuticals Ltd., No. 3:19-cv-21563 (D.N.J. Sep. 17, 2021). [9] Final Written Decision, Foamix Pharmaceuticals Ltd. v. Michael Wilson, IPR2021-00148 (P.T.A.B. June 29, 2022). [10] Motion for Summary Judgment of Non-Infringement and Invalidity, Wilson v. Foamix Pharmaceuticals Ltd., No. 3:19-cv-21563 (D.N.J. Aug. 29, 2022). [11] Opinion, Wilson v. Foamix Pharmaceuticals Ltd., No. 3:19-cv-21563 (D.N.J. Feb. 2, 2023). [12] Notice of Appeal, Wilson v. Foamix Pharmaceuticals Ltd., No. 3:19-cv-21563 (D.N.J. Mar. 2, 2023). [13] U.S. Patent Application Publication No. 2013/0028788. [14] U.S. Patent No. 7,553,814.